Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation  by L'Allier, Philippe L et al.
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ngiotensin-Converting Enzyme Inhibition
n Hypertensive Patients Is Associated With a
eduction in the Occurrence of Atrial Fibrillation
hilippe L. L’Allier, MD,* Anique Ducharme, MD,* Pierre-Fre´de´ric Keller, MD,* Holly Yu, MSPH,†
arie-Claude Guertin, PHD,* Jean-Claude Tardif, MD, FACC*
ontreal, Quebec, Canada; and Bridgewater, New Jersey
OBJECTIVE The objective of this study was to determine the effects of angiotensin-converting enzyme
inhibition (ACEI) versus long-acting calcium-channel blockade (CCB) on atrial fibrillation
(AF) in patients with hypertension.
BACKGROUND Atrial fibrillation is the most common significant cardiac arrhythmia, and angiotensin II has
been implicated in its pathophysiology.
METHODS This was a retrospective, longitudinal cohort study from a database of 8 million people in the
U.S. Patients age 18 years with hypertension were eligible if they filled a prescription for
either an ACEI or a CCB between January 1995 and June 1999. The use of all other
antihypertensive medications was permitted. Patient chronic disease burden was assessed
using a modified Charlson index. Patients were matched on a propensity score generated from
a logistic regression model. A survival analysis approach was used to compare the incidence
of AF between groups. The final cohorts were evaluated until June 2002, and the average
follow-up was 4.5 years.
RESULTS After cohort matching, 10,926 patients were included in the analysis and divided equally into
the ACEI and CCB groups. Mean patient age was 65 years. The adjusted hazards ratio (95%
confidence interval [CI]) in the ACEI versus CCB groups for the entire follow-up period was
0.85 (95% CI: 0.74 to 0.97) for new-onset AF, and the adjusted incidence ratio for
AF-related hospitalizations was 0.74 (95% CI: 0.62 to 0.89).
CONCLUSIONS Angiotensin-converting enzyme inhibition was associated with a reduced incidence of AF for
patients with hypertension in a usual care setting. These results need to be confirmed in a
large-scale randomized clinical trial. (J Am Coll Cardiol 2004;44:159–64) © 2004 by the
American College of Cardiology FoundationO
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itrial fibrillation (AF) is the most prevalent clinically
ignificant cardiac arrhythmia, and related hospitalizations
ave increased dramatically (two- to three-fold) in recent
ears (1). Its occurrence is associated with a two- to
even-fold increase in the risk of ischemic stroke (17-fold
ncrease in patients with underlying rheumatic heart disease)
nd a two-fold increase in mortality (2). Recent reports have
dentified a clear association between hypertension and AF
3–5). Indeed, hypertension is present in a majority of
atients diagnosed with AF and is responsible for more
ases of AF (14%) than any other risk factor (4).
Hypertension affects approximately 20% of the adult
opulation worldwide (or approximately 700 million peo-
le). The prevalence of this condition significantly increases
ith age, and it is estimated that up to 40% of people over
he age of 60 have hypertension. This finding has particular
mportance in light of aging populations. Hypertension is
ssociated with significant morbidity and mortality mainly
rom cardiovascular diseases and especially strokes (6).
From the *Research Center, Montreal Heart Institute, Montreal, Quebec, Canada;
nd the †Institute for Effectiveness Research, Bridgewater, New Jersey. Financed by
n unrestricted grant from Merck & Co., Inc. (Whitehouse Station, New Jersey).
Manuscript received January 8, 2004; revised manuscript received March 17, 2004,
pccepted March 22, 2004.ptimal medical therapy for patients diagnosed with hy-
ertension remains controversial. Because experimental and
arly clinical studies have suggested that inhibition of the
enin-angiotensin system might have a role in preventing
F (7–10), angiotensin-converting enzyme inhibitors
ACEI) could be associated with additional clinical benefits
s compared with other antihypertensive drug classes.
herefore, we assessed the impact of treatment with ACEI
n the occurrence of AF in a large cohort of hypertensive
atients. We used calcium-channel blockers (CCB) as the
lood pressure lowering comparator in this study because
hey have been suggested to have favorable effects on atrial
lectrical remodeling and AF and because they represent the
ost frequently prescribed antihypertensive drug class after
CEI (11,12).
ETHODS
tudy design. This large-scale, longitudinal cohort study
sed integrated medical and pharmacy claims data from a
eographically diverse administrative database of8 million
eople in the U.S. The database is comprised of de-
dentified patient data that was aggregated via medical and
harmacy administrative claims adjudication, originating at
t
a
w
a
a
fi
C
“
l
m
s
t
m
s
i
r
p
p
p
d
u
i
b
e
c
w
d
m
t
N
s
t
i
p
E
w
p
b
l
p
m
f
l
b
e
c
w
b
t
t
m
l
d
r
i
h
a
a
m
f
m
fi
e
O
l
v
p
m
A
c
a
n
b
o
i
t
a
p
e
S
t
n
C
i
a
s
m
l
e
a
r
G
160 L’Allier et al. JACC Vol. 44, No. 1, 2004
ACEI Reduces AF in Hypertension July 7, 2004:159–64he point of service (hospital, physician’s office, pharmacy,
nd so forth) using diagnostic and procedural codes that
ere entered by the provider. Data are subjected to elaborate
lgorithms before being entered into the database to ensure
ccuracy. Patients 18 years of age were eligible if they
lled a prescription for either an ACEI or a long-acting
CB between January 1, 1995, and June 30, 1999 (the
index prescription”). Patients were also required to have at
east one diagnosis of hypertension from one or more
edical visits during the time period six months before and
ubsequent to the index prescription. Patients were required
o be continuously medical and pharmacy benefit-eligible six
onths before the index prescription and during the entire
tudy follow-up period. In addition, at least six months of
ndex drug exposure during the study follow-up period was
equired. Furthermore, any eligible patients who had a
rescription of any antihypertensive agent before the index
rescription were taken out of the study. Any eligible ACEI
atients who used CCB or CCB patients who used ACEI
uring the study follow-up period were excluded. However,
se of other antihypertensive medications subsequent to the
ndex prescription was permitted, and was evaluated for
oth comparison groups. The final cohorts in the study were
valuated until June 30, 2002, unless patients either de-
eased or lost medical or pharmacy eligibility (these patients
ere censored at the onset of benefit termination or date of
eath).
Patient chronic disease burden was assessed using a
odified Charlson index (13). The Charlson index utilized
he presence of the International Classification of Diseases-
inth Revision diagnosis codes for encounters during the
ix-month period before the index prescription to identify
he presence of 17 chronic diseases, including myocardial
nfarction (MI), congestive heart failure (CHF), diabetes,
eripheral vascular disease, dementia, cancer, and others.
ach condition was assigned a weight from 1 to 6, and they
ere summed to derive an overall composite index for each
atient that represents the patient’s total chronic disease
urden.
The medication possession ratio was used as a proxy of
ength of index medication exposure during the follow-up
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACEI  angiotensin-converting enzyme
inhibitor/inhibition
AF  atrial fibrillation
CCB  calcium-channel blocker
CHD  coronary heart disease
CHF  congestive heart failure
CI  confidence interval
LA  left atrial
LV  left ventricular
MI  myocardial infarctioneriod. It was defined as the total days’ supply of index Nedication over the study duration divided by the total
ollow-up time on each patient and multiplied by 100.
Propensity scoring was used to minimize potential base-
ine differences that could bias final outcome measurements,
ecause patient demographic characteristics and pre-
xisting medical conditions may have influenced a physi-
ian’s choice of antihypertensive therapy. Logistic regression
as used to create propensity scores and to match cohorts
etween the comparison groups. The propensity score
ranslates to the conditional probability of receiving a
reatment given pre-treatment characteristics. The index
edication was modeled as the dependent variable in the
ogistic regression while adjusting for significant indepen-
ent variables. These factors were identified by clinical
ationale and a stepwise model selection process. They
ncluded age, gender, prior diagnosis of CHF, coronary
eart disease (CHD), renal disease, stroke, acute MI,
ngina, complicated hypertension, AF, hyperlipidemia, di-
betes, and Charlson index. Clinically valid interactions of
edical conditions were also adjusted in the model. Patients
rom each comparison group were matched based on a
inimum difference in propensity scores generated from the
nal logistic regression model, with the difference not
xceeding 0.01.
utcomes. The purpose of the study was to compare
ong-term occurrence of AF between patients on ACEI
ersus those on CCB. The comparison of ACEI and CCB
atients that were matched based on the propensity scoring
ethodology outlined above is presented.
The main outcome for this study was the occurrence of
F during follow-up in two different ways: new-onset AF
ondition and AF-related hospitalizations. The presence of
new-onset AF condition was evaluated and defined as any
ew diagnosis of AF during follow-up. The time elapsed
etween the index prescription and the first onset of newly
ccurring diagnosis of AF was also assessed. Inpatient care
ncidence was measured by the presence of any hospitaliza-
ion related to a diagnosis of AF. Study outcome was
ssessed at three time periods: three years after index
rescription, five years after index prescription, and for the
ntire follow-up period.
tatistical analysis. A survival analysis approach was used
o compare the time elapsed from index prescription to
ewly diagnosed AF between patients on ACEI versus on
CB. The analysis of newly diagnosed AF was performed
n patients without a prior history of AF. The survival
nalyses were conducted in two ways: using Kaplan-Meier
urvival curves and using proportional hazards regression
odels.
The incidence rates per 1,000 person-years were calcu-
ated for AF. Poisson regression models were used to
stimate the incidence ratio between the comparison groups
nd the corresponding 95% confidence interval for AF-
elated hospitalizations. We fitted the models using the
enmod procedure (SAS version 8.2, SAS Institute, Cary,
orth Carolina ). The covariates used in the final Poisson
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July 7, 2004:159–64 ACEI Reduces AF in Hypertensionegression and the proportional hazards regression were
ased on clinical rationale and a stepwise statistical model
election process. They included gender, age, medication
ossession ratio, Charlson index, and the presence (yes/no)
f pre-existing conditions including CHF, CHD, renal
isease, stroke, hyperlipidemia, and diabetes. Only signifi-
ant covariates at p  0.10 level remained in the final
odel. SAS version 8.2 (SAS Institute) was used for all
tatistical analyses.
ESULTS
atient characteristics. There were 18,199 patients who
et the study inclusion criteria; 12,608 (69%) used ACEI
hile 5,591 used CCB. After cohort matching using pro-
ensity score, there were 5,463 matched patients in each
roup. Clinical and demographic characteristics were nearly
dentical in both groups (Table 1). Mean age was 65 years in
oth groups, and the prevalence of CHF, diabetes, and
troke in the ACEI and CCB groups, respectively, was 3.7%
ersus 3.6%, 9.9% versus 10.1%, and 6.4% versus 6.7%. A
revious history of AF was present in 2.4% versus 2.3% of
atients in the ACEI and CCB groups, respectively. The
edication possession ratio was 65.2% for the ACEI group
nd 64.2% for CCB group, while the average length of
ollow-up was 4.6 years versus 4.2 years for the ACEI versus
able 1. Baseline Patient Characteristics After Cohort
atching (ACEI Versus Long-Acting CCB)
ACEI CCB
atients (n) 5,463 5,463
ge (mean) 65 65
emale (%) 54.2 54.0
harlson index (mean) 0.626 0.625
edication possession ratio (%) 65.2 64.2
ength of follow-up (yrs) 4.6 4.2
ny use of other antihypertensives
During follow-up (%) 48.3 48.1
Beta-blockers (%) 15.5 19.6
Diuretics (%) 40.8 37.6
Thiazides (%) 17.6 12.4
Loop (%) 16.6 13.7
Potassium-sparing (%) 8.2 14.6
Diuretic combination (%) 6.3 3.9
Alpha-blockers (%) 8.8 9.9
Hydralazine (%) 0.6 0.6
re-existing condition
ngina (%) 10.4 11.0
MI (%) 1.8 1.9
HF (%) 3.7 3.6
HD (%) 15.2 16.0
troke (%) 6.4 6.7
omplicated hypertension (%) 3.1 3.0
enal disease (%) 1.2 1.3
yperlipidemia (%) 13.7 13.7
iabetes (%) 9.9 10.1
istory of AF (%) 2.4 2.3
CEI  angiotensin-converting enzyme inhibitor; AF  atrial fibrillation; AMI 
cute myocardial infarction; CCB  long-acting calcium-channel blocker; CHD 
oronary heart disease; CHF  congestive heart failure.CB patients, respectively. wsage of other antihypertensive agents. The use of other
ntihypertensive agents during the study follow-up period
as also investigated. Almost half of the cohort (48.3% of
CEI and 48.1% of CCB) used at least one other antihy-
ertensive agent during the study follow-up period. Diuret-
cs were the most frequently prescribed adjunctive medica-
ion in both groups (40.8% and 37.6% in the ACEI and
CB groups, respectively). Proportionally more patients in
he ACEI group received thiazides (17.6% vs. 12.4%) while
ore patients in the CCB group received beta-blockers
19.6% vs. 15.5%).
ain outcome: AF. INCIDENCE RATE OF NEW-ONSET
F. The incidence rate of new-onset AF during the entire
tudy follow-up period was less in the ACEI group as
ompared with the CCB group (17.9 vs. 18.9 per 1,000
atient-years). The hazard ratio for patients treated with an
CEI was 0.85 (95% confidence interval [CI]: 0.74 to 0.97)
Table 2).
IME TO NEW-ONSET AF. The average number of months
least squares mean) to first onset of AF was 29.5 versus
6.1 (difference 3.4 months (95% CI: 0.72 to 6.04) in the
CEI and CCB groups, respectively. The Kaplan-Meier
urves showing time to occurrence of new-onset AF in
atients treated with an ACEI versus a CCB are illustrated
n Figure 1 (p  0.0183). The absolute incidence of AF in
his cohort of hypertensive patients was 10.6% versus 13.0%
t six years and 19.4% versus 22.1% at seven years in the
CEI and CCB groups, respectively (Kaplan-Meier esti-
ates).
NCIDENCE RATE OF AF-RELATED HOSPITALIZATION. The
ncidence rate of AF-related hospitalizations during the
ntire study follow-up period was less in the ACEI group as
ompared with the CCB group (8.5 vs. 11.9 per 1,000
atient-years). The incidence ratio for patients treated with
n ACEI was 0.74 (95% CI: 0.62 to 0.89). This difference
as also apparent at three years and was still present at five
ears (Table 3).
We further assessed the impact of therapy in patients
ith a prior history of AF and in those without. As shown
n Table 4, there was an incremental benefit of ACEI to
revent AF-related hospitalizations in patients with a prior
iagnosis of this arrhythmia as compared with those
able 2. Occurrence of Atrial Fibrillation According to
ntihypertensive Treatment: IR per 1,000 Person-Years of
ew-Onset Atrial Fibrillation, Adjusted Hazard Ratio, and
5% CI
Matched Cohorts ACEI IR CCB IR
ACEI versus
CCB Ratio
(95% CI)
hree years 18.4 19.9 0.92 (0.78–1.09)
ive years 19.9 20.6 0.90 (0.78–1.03)
ntire follow-up 17.9 18.9 0.85 (0.74–0.97)
CEI  angiotensin-converting enzyme inhibitor; CCB  long-acting calcium
hannel blocker; CI  confidence interval; IR  incidence rates.ithout.
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ACEI Reduces AF in Hypertension July 7, 2004:159–64ISCUSSION
his large-scale observational study provided us with a
nique opportunity to assess the impact of medical therapy
n the occurrence of AF in patients with hypertension.
ngiotensin-converting enzyme inhibition was associated
ith a significant reduction in the incidence of AF during
.5-year follow-up as compared with calcium-channel
lockade. In addition, we found that patients with a prior
iagnosis of AF benefited most from ACEI with regard to
ecurrence.
Atrial fibrillation has been described as one of two
merging cardiovascular epidemics at the turn of the century
14). Indeed, hospitalizations for AF from 1985 through
999 increased from 154,086 to 376,487 for a first-listed
iagnosis and from 787,750 to 2,283,673 for any diagnosis
n the U.S. In addition, the prevalence of this age-related
rrhythmia is expected to further increase with the aging
opulation (1,14). Therefore, any therapy that reduces AF
n high-risk populations will likely have a significant impact
n resource allocation.
Hypertension has been shown to be the most prevalent,
ndependent, and potentially modifiable risk factor for AF
3,4). Of note, the absolute incidence of AF at six and seven
igure 1. Kaplan-Meier curves for time to first occurrence of atrial fib
alcium-channel blocker.
able 3. Occurrence of Atrial Fibrillation According to
ntihypertension Treatment: IR per 1,000 Person-Years of
trial Fibrillation-Related Hospitalization, Adjusted Incidence
atio, and 95% CI
Matched Cohorts ACEI IR CCB IR
ACEI Versus
CCB Ratio
(95% CI)*
hree years 7.7 11.8 0.65 (0.54–0.83)
ive years 8.8 11.9 0.74 (0.61–0.89)
ntire follow-up 8.5 11.9 0.74 (0.62–0.89)
Poisson regression.
ACEI  angiotensin-converting enzyme inhibitor; CCB  long-acting calcium-Ihannel blocker; CI  confidence interval; IR  incidence rates.ears in our study was somewhat higher than expected,
lthough very limited data are available from previous
tudies of hypertensive patients (4). Myocardial adaptation
o chronically elevated blood pressure has been very well
ocumented and includes left ventricular (LV) hypertrophy,
eft atrial (LA) enlargement, and modifications of atrial
echanical function. These compensatory changes second-
ry to hypertension may promote atrial arrhythmias. Left
entricular mass has been identified as an independent
redictor of AF in hypertensive patients (15,16). In the
ramingham cohort, the risk of developing AF increased by
8% for each 4-mm increase in LV thickness (4). Left atrial
nlargement is a known predisposing factor for the devel-
pment of AF. Numerous cohort studies have reported a
ignificant correlation between LA size and AF (3,4,15).
eft atrial enlargement occurs frequently in hypertensive
atients and may precede LV hypertrophy in some cases
17). Numerous studies have reported that the magnitude of
A enlargement correlated with the severity of hypertension
18,19). Furthermore, atrial stretch has been shown to
horten the effective refractory period and lengthen intra-
trial conduction time (20,21). These findings support the
ypothesis that hypertension predisposes to AF through
trial enlargement and electrophysiologic remodeling.
There is evidence suggesting a role for the renin-
ngiotensin system in the pathophysiology of AF. Angio-
ensin II has been shown to increase atrial pressure and
tretch, which are associated with electrophysiologic
hanges described above, thereby promoting AF (22). An-
iotensin II is also a potent promoter of fibrosis, leading to
ardiac myoblast proliferation and reduced collagenase ac-
ivity (23–25). Atrial fibrosis is a frequent finding in patients
ith AF, which may explain intraatrial conduction distur-
ances and the persistent susceptibility for AF (26). In-
reased ACE expression and alterations in the angiotensin
ion (AF). ACEI  angiotensin-converting enzyme inhibitor; CCB rillatI receptor expression have been observed in the atria of AF
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July 7, 2004:159–64 ACEI Reduces AF in Hypertensionatients. Furthermore, an ACEI-dependent increase in
evels of activated extracellular signal-regulated kinases
rk1/Erk2 and Erk-activating kinases MEK1/2 was found
n patients with AF by examining atrial tissue samples
btained during open-heart surgery (27,28). There is also
vidence suggesting that ACE polymorphism also plays a
ole in predisposing to AF (29). The ACEI enalapril has
een shown to decrease mitogen-activated protein kinase
ctivation, atrial fibrosis, and AF promotion in a dog model
f heart failure (30). Enalapril was also shown to decrease
trial structural and functional remodeling in the same
odel (7). In addition, the angiotensin II receptor antago-
ist candesartan was reported to prevent the promotion of
F by suppressing the development of structural remodel-
ng (interstitial fibrosis) in a dog rapid pacing model (31).
arly clinical trials evaluating the effect of ACEI in patients
ith reduced LV function secondary to acute MI and
ngiotensin receptor antagonists in patients with AF who
nderwent cardioversion have reported significant reduc-
ions in the incidence and recurrence of atrial arrhythmias,
espectively (8,9). More recently, treatment with enalapril
as reported to reduce the recurrence of AF after cardio-
ersion in patients with chronic AF treated with amioda-
one (32,33). Furthermore, our group has published results
trongly suggesting a beneficial effect of enalapril on AF
evelopment in patients with chronic LV dysfunction (10).
In addition to its role in atrial structural remodeling,
ngiotensin II has also been shown to modify electrophysi-
logic remodeling. The atrial effective refractory period has
een shown to shorten in chronic AF (34). Inhibition of
ndogenous angiotensin II (either through ACEI or angio-
ensin II type 1 receptor antagonism) has been shown to
revent atrial effective refractory period shortening and loss
f atrial effective refractory period rate adaptation during
apid atrial pacing (22). These results taken together provide
wo plausible explanations for the preventive effects of
CEI against AF, namely via prevention of structural and
lectrophysiologic remodeling.
linical implications. Although a beneficial effect of ACEI
Table 4. IR per 1,000 Person-Years of AF-Re
and 95% CI
Matched Cohorts
Patients with prior AF condition
(n  258, 130 in ACEI, 128 in CCB)
Three years
Five years
Entire follow-up
Patients without prior AF condition
(n  10,668, 5,333 in ACEI, 5,335 in CCB)
Three years
Five years
Entire follow-up
*Poisson regression.
ACEI  angiotensin-converting enzyme inhibitor; AF 
CI  confidence intervals; IR  incidence rates.n AF has been convincingly demonstrated in patients withV systolic dysfunction, hypertension is a much more preva-
ent condition, and extending the clinical benefits of ACEI to
his patient population has important clinical implications. Our
esults suggest that treatment of hypertension with ACEI
ather than other antihypertensive medications may signifi-
antly decrease the occurrence of AF.
tudy limitations. Treatment allocation was not random-
zed, and this large-scale longitudinal cohort study is,
herefore, subject to potential confounders like treatment
election bias. However, propensity scoring was used to
inimize or adjust for as many of these factors as possible.
onclusions. Angiotensin-converting enzyme inhibition
as associated with a reduced incidence of AF for patients
ith hypertension in a managed care setting. These results
eed to be confirmed in a large-scale randomized clinical
rial.
eprint requests and correspondence: Dr. Jean-Claude Tardif,
ontreal Heart Institute, 5000 Belanger Street, Montreal, Que-
ec, Canada H1T 1C8. E-mail: jean-claude.tardif@icm-mhi.org.
EFERENCES
1. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospi-
talization for atrial fibrillation in the United States, 1985 through
1999: implications for primary prevention. Circulation 2003;108:
711–6.
2. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation: executive
summary—a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the Euro-
pean Society of Cardiology Committee for Practice Guidelines and
Policy Conferences (Committee to Develop Guidelines for the Man-
agement of Patients With Atrial Fibrillation): developed in collabo-
ration with the North American Society of Pacing and Electrophysi-
ology. Circulation 2001;104:2118–50.
3. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors
for atrial fibrillation in older adults. Circulation 1997;96:2455–61.
4. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence,
prognosis, and predisposing conditions for atrial fibrillation:
population-based estimates. Am J Cardiol 1998;82:2N–9N.
5. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural
history of atrial fibrillation: clinical implications. J Am Coll Cardiol
2001;37:371–8.
6. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of
Hospitalizations, Adjusted Incidence Ratio,
EI IR CCB IR
ACEI Versus CCB Ratio
(95% CI)*
01.9 175.3 0.58 (0.37–0.90)
12.9 201.1 0.56 (0.39–0.81)
09.7 201.8 0.55 (0.38–0.78)
5.8 8.5 0.68 (0.52–0.90)
6.6 8.4 0.80 (0.64–0.99)
6.7 8.5 0.82 (0.67–1.01)
l fibrillation; CCB  long-acting calcium-channel blocker;lated
AC
1
1
1
atriathe Joint National Committee on Prevention, Detection, Evaluation,
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
164 L’Allier et al. JACC Vol. 44, No. 1, 2004
ACEI Reduces AF in Hypertension July 7, 2004:159–64and Treatment of High Blood Pressure: the JNC 7 report. JAMA
2003;289:2560–72.
7. Shi Y, Li D, Tardif JC, et al. Enalapril effects on atrial remodeling and
atrial fibrillation in experimental congestive heart failure. Cardiovasc
Res 2002;54:456–61.
8. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the
incidence of atrial fibrillation after acute myocardial infarction in patients
with left ventricular dysfunction. Circulation 1999;100:376–80.
9. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to
maintain sinus rhythm in patients with long-lasting persistent atrial
fibrillation: a prospective and randomized study. Circulation 2002;106:
331–6.
0. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the
incidence of atrial fibrillation in patients with left ventricular dysfunc-
tion: insight from the Studies Of Left Ventricular Dysfunction
(SOLVD) trials. Circulation 2003;107:2926–31.
1. Fareh S, Benardeau A, Nattel S. Differential efficacy of L- and T-type
calcium channel blockers in preventing tachycardia-induced atrial
remodeling in dogs. Cardiovasc Res 2001;49:762–70.
2. Siegel D, Lopez J. Trends in antihypertensive drug use in the United
States: do the JNC V recommendations affect prescribing? Fifth Joint
National Commission on the Detection, Evaluation, and Treatment of
High Blood Pressure. JAMA 1997;278:1745–8.
3. Charlson ME, Pompei P, MacKenzie CR. A new method of classi-
fying prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987;40:373–83.
4. Braunwald E. Shattuck lecture—cardiovascular medicine at the turn of
the millennium: triumphs, concerns, and opportunities. N Engl J Med
1997;337:1360–9.
5. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the
predictive parameters for the onset of atrial fibrillation in patients with
essential hypertension. Am Heart J 2000;139:814–9.
6. Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in
hypertension: predictors and outcome. Hypertension 2003;41:218–23.
7. Miller JT, O’Rourke RA, Crawford MH. Left atrial enlargement: an early
sign of hypertensive heart disease. Am Heart J 1988;116:1048–51.
8. Vaziri SM, Larson MG, Lauer MS, et al. Influence of blood pressure
on left atrial size: the Framingham Heart study. Hypertension 1995;
25:1155–60.
9. Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size
in hypertensive patients with left ventricular hypertrophy: the Losartan
Intervention For Endpoint Reduction in Hypertension (LIFE) study.
Hypertension 2002;39:739–43.
0. Solti F, Vecsey T, Kekesi V, et al. The effect of atrial dilatation on the
genesis of atrial arrhythmias. Cardiovasc Res 1989;23:882–6.1. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period
and vulnerability to atrial fibrillation in the isolated Langendorff-
perfused rabbit heart. Circulation 1997;96:1686–95.
2. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist
prevents electrical remodeling in atrial fibrillation. Circulation 2000;
101:2612–7.
3. Pages G, Lenormand P, L’Allemain G. Mitogen-activated protein
kinases p42mapk and p44mapk are required for fibroblast prolifera-
tion. Proc Natl Acad Sci USA 1993;90:8319–23.
4. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in
cultured adult rat cardiac fibroblasts: response to angiotensin II and
aldosterone. J Mol Cell Cardiol 1994;26:809–20.
5. Zou Y, Komuro I, Yamazaki T, et al. Cell type-specific angiotensin
II-evoked signal transduction pathways: critical roles of Gbetagamma
subunit, Src family, and Ras in cardiac fibroblasts. Circ Res 1998;82:
337–45.
6. Everett TH, 4th, Li H, Mangrum JM, et al. Electrical, morphological,
and ultrastructural remodeling and reverse remodeling in a canine
model of chronic atrial fibrillation. Circulation 2000;102:1454–60.
7. Goette A, Staack T, Rocken C, et al. Increased expression of
extracellular signal-regulated kinase and angiotensin-converting en-
zyme in human atria during atrial fibrillation. J Am Coll Cardiol
2000;35:1669–77.
8. Goette A, Arndt M, Rocken C, et al. Regulation of angiotensin II
receptor subtypes during atrial fibrillation in humans. Circulation
2000;101:2678–81.
9. Gensini F, Padeletti L, Fatini C, et al. Angiotensin-converting
enzyme and endothelial nitric oxide synthase polymorphisms in
patients with atrial fibrillation. Pacing Clin Electrophysiol 2003;26:
295–8.
0. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting
enzyme inhibition on the development of the atrial fibrillation sub-
strate in dogs with ventricular tachypacing-induced congestive heart
failure. Circulation 2001;104:2608–14.
1. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II
type 1 receptor antagonist on electrical and structural remodeling in
atrial fibrillation. J Am Coll Cardiol 2003;41:2197–204.
2. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus
rhythm maintenance after external cardioversion of long-standing
persistent atrial fibrillation: results of a prospective and controlled
study. Eur Heart J 2003;24:2090–8.
3. Heidbuchel H. A paradigm shift in treatment for atrial fibrillation:
from electrical to structural therapy? Eur Heart J 2003;24:2077–8.
4. Wijffels MC, Kirchhof CJ, Dorland R, et al. Electrical remodeling due
to atrial fibrillation in chronically instrumented conscious goats: roles
of neurohumoral changes, ischemia, atrial stretch, and high rate of
electrical activation. Circulation 1997;96:3710–20.
